BI-836826

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-836826
Drug Alias NamemAb-37.2BI-836826mAb-37.1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsLeukocyte antigen CD37 antagonists
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A